Johnson & Johnson Services, Inc.
Uses biomarkers to advance drug development and personalized treatment approaches across oncology, immunology, and neuroscience
Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →
Key metrics · each point sourced
Stated objectives
Achieve full-year 2025 sales of $93.5B-$93.9B, representing growth of 5.4%-5.9%
sourceImprove adjusted pretax operating margin by approximately 300 basis points driven by cost savings and reduced acquired IPR&D costs
sourceAchieve 2026 top-line growth of more than 5%, exceeding consensus of ~4.6%
sourceAchieve 2026 adjusted EPS approximately $0.05 above consensus of $11.39, implying ~$11.44
sourceSubmit OTTAVA robotic surgical system for regulatory approval in the United States
sourceAchieve higher operational sales growth in both Innovative Medicine and MedTech segments in 2026
sourceImprove MedTech growth and margins by completing the pending separation of the Orthopaedics franchise
sourceStrengthen presence in the neurological and psychiatric drug market via acquisition of Intra-Cellular Therapies
sourceDevelop and deploy Ottava next-generation robotic surgery platform with AI-enabled ecosystem
sourceJ&J expects sales growth in both Innovative Medicine and MedTech segments to be higher in 2026
sourceRelationship graph · 1255 connections
Where sources disagree
We surface conflicts between sources rather than hiding them.
Both facts report the adjusted_net_earnings attribute for the same entity (Johnson & Johnson Services, Inc.) at the same observation timestamp (2026-07-15 00:00:00), but with different values: 6699 USD vs 7081 USD. The difference of 382 USD (~5.7%) represents a material discrepancy that cannot be reconciled without additional context (such as different data sources, rounding, or revisions).
Same entity (Johnson & Johnson Services, Inc.) has two different adjusted_eps values (2.90 USD vs 2.77 USD) recorded for the identical observation timestamp (2026-07-15). This is a direct value conflict—adjusted EPS cannot simultaneously be both 2.90 and 2.77 for the same company on the same date.
Same entity (Johnson & Johnson Services, Inc.), same attribute (free_cash_flow), same observation timestamp (2026-07-15 00:00:00), but conflicting values: 8700 USD vs 6214 USD. This represents a ~29% discrepancy and suggests either data from different sources, calculation method differences, or a data quality issue.